JP2022540446A5 - - Google Patents

Info

Publication number
JP2022540446A5
JP2022540446A5 JP2022500898A JP2022500898A JP2022540446A5 JP 2022540446 A5 JP2022540446 A5 JP 2022540446A5 JP 2022500898 A JP2022500898 A JP 2022500898A JP 2022500898 A JP2022500898 A JP 2022500898A JP 2022540446 A5 JP2022540446 A5 JP 2022540446A5
Authority
JP
Japan
Prior art keywords
rna
composition according
rhodopsin
protein
pathogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022500898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041634 external-priority patent/WO2021007529A1/en
Publication of JP2022540446A publication Critical patent/JP2022540446A/ja
Publication of JP2022540446A5 publication Critical patent/JP2022540446A5/ja
Pending legal-status Critical Current

Links

JP2022500898A 2019-07-10 2020-07-10 Rna標的ノックダウン及び置換の組成物及び使用方法 Pending JP2022540446A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962872604P 2019-07-10 2019-07-10
US62/872,604 2019-07-10
US202062968819P 2020-01-31 2020-01-31
US62/968,819 2020-01-31
PCT/US2020/041634 WO2021007529A1 (en) 2019-07-10 2020-07-10 Rna-targeting knockdown and replacement compositions and methods for use

Publications (2)

Publication Number Publication Date
JP2022540446A JP2022540446A (ja) 2022-09-15
JP2022540446A5 true JP2022540446A5 (https=) 2023-07-18

Family

ID=71995058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500898A Pending JP2022540446A (ja) 2019-07-10 2020-07-10 Rna標的ノックダウン及び置換の組成物及び使用方法

Country Status (7)

Country Link
US (1) US20210009987A1 (https=)
EP (1) EP3997227A1 (https=)
JP (1) JP2022540446A (https=)
CN (1) CN114450031A (https=)
AU (1) AU2020310201A1 (https=)
CA (1) CA3145309A1 (https=)
WO (1) WO2021007529A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160052A2 (en) 2010-06-18 2011-12-22 The University Of North Carolina At Chapel Hill Methods and compositions for sequence specific rna endonucleases
EP3901262A1 (en) * 2020-04-20 2021-10-27 Universität Regensburg Compositions for use in treating autosomal dominant best1-related retinopathies
EP4216964A4 (en) * 2020-09-24 2025-02-12 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing apoe expression
EP4291654A2 (en) 2021-02-12 2023-12-20 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
WO2022221278A1 (en) * 2021-04-12 2022-10-20 Locanabio, Inc. Compositions and methods comprising hybrid promoters
WO2022241059A2 (en) * 2021-05-11 2022-11-17 Mammoth Biosciences, Inc. Effector proteins and methods of use
WO2023015153A2 (en) * 2021-08-02 2023-02-09 President And Fellows Of Harvard College ANTISENSE OLIGONUCLEOTIDE TARGETING APOE ε4 AND USES THEREOF
EP4419688A2 (en) * 2021-10-21 2024-08-28 Prime Medicine, Inc. Genome editing compositions and methods for treatment of usher syndrome type 3
US12173368B2 (en) * 2022-03-11 2024-12-24 New England Biolabs, Inc. Compositions and analysis of dephosphorylated oligoribonucleotides
EP4493702A4 (en) * 2022-03-18 2026-04-01 Univ Florida METHODS AND COMPOSITIONS FOR TREATING TNNT2-RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR
WO2023215761A1 (en) * 2022-05-03 2023-11-09 Tacit Therapeutics, Inc. Localization of trans-splicing nucleic acid molecules to and within the cellular nucleus
WO2024196955A2 (en) * 2023-03-20 2024-09-26 Duke University Apoe-targeted microglia-specific gene therapy for neurological diseases
WO2025043118A1 (en) * 2023-08-23 2025-02-27 Ohio State Innovation Foundation Making tiny rnas inside the cell
WO2025043278A1 (en) * 2023-08-25 2025-03-06 PYC Therapeutics Limited Gene-mediated conditions
WO2025159427A1 (ko) * 2024-01-26 2025-07-31 서울대학교산학협력단 신규한 apoe 안티센스 올리고뉴클레오타이드 및 이의 용도
WO2025217591A1 (en) * 2024-04-12 2025-10-16 Strand Therapeutics Inc. Human-derived synthetic regulators and uses thereof
WO2026010243A1 (ko) * 2024-07-03 2026-01-08 주식회사 아바타테라퓨틱스 Crispr/cas 시스템을 사용하는 best1 유전자 편집 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714007T3 (es) 2007-04-09 2019-05-24 Univ Florida Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
CN101895633A (zh) 2010-07-14 2010-11-24 中兴通讯股份有限公司 一种移动终端及其解锁方法
WO2012068627A1 (en) 2010-11-24 2012-05-31 The University Of Western Australia Peptides for the specific binding of rna targets
US9951349B2 (en) * 2011-09-27 2018-04-24 Yale University Compositions and methods for transient expression of recombinant RNA
DK2784157T3 (da) 2011-10-21 2019-10-21 Univ Kyushu Nat Univ Corp Designfremgangsmåde til et rna-bindende protein under anvendelse af ppr-motiv og anvendelse deraf
US9850269B2 (en) * 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US10330674B2 (en) 2015-01-13 2019-06-25 Massachusetts Institute Of Technology Pumilio domain-based modular protein architecture for RNA binding
EP3858992A1 (en) * 2015-03-13 2021-08-04 The Jackson Laboratory A three-component crispr/cas complex system and uses thereof
EP3289080B1 (en) * 2015-04-30 2021-08-25 The Trustees of Columbia University in the City of New York Gene therapy for autosomal dominant diseases
US10876101B2 (en) 2017-03-28 2020-12-29 Locanabio, Inc. CRISPR-associated (Cas) protein
CN108690861A (zh) * 2017-04-10 2018-10-23 肖晓莺 用于早期乳腺癌症诊断的微小核糖核酸
US10392616B2 (en) 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
US10476825B2 (en) 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions

Similar Documents

Publication Publication Date Title
JP2022540446A5 (https=)
Patil et al. Rapid evolution and diversification of mammalian α-defensins as revealed by comparative analysis of rodent and primate genes
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
Auricchio et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents
US20230053353A1 (en) Targeting transfer rna for the suppression of nonsense mutations in messenger rna
JP2024520528A5 (https=)
JP2017506885A (ja) アデノ随伴ウイルスベクターの高力価産生
JP2018078898A (ja) 肝特異的核酸調節要素ならびにその方法および用途
CN111218446B (zh) 一种肝脏特异性启动子及其应用
JP2021532776A5 (https=)
JP2018538003A (ja) 内皮特異的核酸調節エレメントならびにその方法および使用
CN110393791A (zh) hnRNPA2B1的抗感染作用及其应用
US20220162638A1 (en) Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
JP2024523394A5 (https=)
JP2024518817A5 (https=)
JP2023544702A5 (https=)
KR20250053925A (ko) CRISPR-Cas13 시스템 및 이의 용도
JP2022542294A5 (https=)
JP2024529108A5 (https=)
JP2006524491A5 (https=)
JP7626423B6 (ja) 線維症治療薬
JP2021529519A5 (https=)
US20230220361A1 (en) Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells
JP2024516079A5 (https=)
JP3913171B2 (ja) 新規ヒトキネシン関連遺伝子の核酸、該核酸によってコードされるタンパク質、その部分ペプチド、および該核酸等からなる抗癌剤